NCT00526617: A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients |
|
|
| Completed | 1 | 41 | NA | ABT-888, Temozolomide, Temodar, TMZ | AbbVie | Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma | 06/10 | | | |
